{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.273","value":"4.42"},{"groupId":"OG001","spread":"13.884","value":"1.11"},{"groupId":"OG002","spread":"22.276","value":"0.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.916","value":"1.17"},{"groupId":"OG001","spread":"21.279","value":"5.56"},{"groupId":"OG002","spread":"17.713","value":"-0.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 9, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.650","value":"-3.29"},{"groupId":"OG001","spread":"19.685","value":"15.00"},{"groupId":"OG002","spread":"21.398","value":"1.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 13, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.326","value":"0.17"},{"groupId":"OG001","spread":"17.889","value":"10.00"},{"groupId":"OG002","spread":"23.551","value":"3.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.905","value":"4.25"},{"groupId":"OG001","spread":"22.546","value":"8.33"},{"groupId":"OG002","spread":"18.285","value":"5.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"Cycle 21, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.422","value":"4.00"},{"groupId":"OG001","spread":"10.607","value":"-2.50"},{"groupId":"OG002","spread":"7.071","value":"5.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Cycle 25, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.619","value":"-2.67"},{"groupId":"OG001","spread":"7.071","value":"-5.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 29, Day 1"},{"categories":[{"measurements":[{"comment":"Not estimable due to sample size","groupId":"OG000","spread":"NA","value":"-3.00"},{"comment":"Not estimable due to sample size","groupId":"OG001","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 33, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.546","value":"-1.50"},{"groupId":"OG001","spread":"21.047","value":"-9.52"},{"groupId":"OG002","spread":"3.536","value":"12.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Safety Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"Mean change from baseline at safety follow-up visit in EQ-5D-5L visual analogue score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' An increasing score indicates improvements from baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG000","title":"Cohort 1: ENKTL"},{"description":"Participants with other R/R mature T-cell neoplasms \\[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG001","title":"Cohort 2: PTCL-NOS, AITL, and ALCL"},{"description":"Participants with R/R cutaneous T-cell lymphoma \\[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG002","title":"Cohort 3: MF and SS"}],"paramType":"MEAN","populationDescription":"Safety analysis set includes all participants who received at least one dose of study drug. The number analyzed represents participants who completed the questionnaire.","reportingStatus":"POSTED","timeFrame":"Baseline and on Day 1 in Cycles 5, 9, 13, 17, 21, 25, 29, and 33 (21 days per cycle) and safety follow-up visit (up to 30 days after end of treatment; up to approximately 3 years and 1 week)","title":"Quality of Life Assessment: EQ-5D-5L Change From Baseline in Visual Analogue Score","type":"SECONDARY","unitOfMeasure":"Score on a scale"}